Russell Lebovitz, Amprion CEO
October 8, 2024 11:24 AM EDT
Financing
R&D

Ex­clu­sive: A small San Diego biotech wants to change how Parkin­son’s dis­ease is di­ag­nosed

Ryan Cross

Senior Science Correspondent

A pro­tein called al­pha-synu­cle­in that ac­cu­mu­lates and rav­ages the brains of some peo­ple with Parkin­son’s dis­ease is the tar­get of sev­er­al ex­per­i­men­tal drugs. Un­til re­cent­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Pfiz­er's for­mer top ex­ec­u­tives pitched changes to board as part of ac­tivist's plan

John Maraganore's RNAi biotech City Ther­a­peu­tics de­buts with $135M Se­ries A

Pfiz­er culls RSV treat­ment from Re­Vi­ral ac­qui­si­tion

Ex­clu­sive: Tiny start­up with big vi­sion to ex­tend healthspan by 20 years says it dis­cov­ered an ‘At­las of ...

Sage faces third study fail in six months as Alzheimer's can­di­date miss­es Phase 2 goal

Astel­las places new bet on gene ther­a­py in $50M up­front deal with UK start­up

A service from the Financial Times